Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (21415)	9/22/2006 4:54:54 PM
From: Ploni	Read Replies (1) \| Respond to of 52153

Thanks for the replies. I hadn't realized that anyone was watching PARD. I've never owned any, but am impressed with the reports that picoplatin has very low toxicity compared to other platinum drugs (which apparently cause moderate or severe neuropathy that is so bad that half of the patients have to stop taking them). But of course we don't yet know how effective picoplatin will be, and PARD's low trading volume, high volatility and reverse split also make me nervous. I was surprised that the stock has crashed to below where a big investment was made recently, and I'm sure that those investors were also surprised. I also worry when I see a drug start out in one firm (AnorMED) and then be licensed to another; that makes me wonder if AnorMED had some data suggesting it wouldn't be a valuable drug, or if AnorMED just decided they wanted to concentrate on other projects.